A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
However, Erasmas and several non-avout companions, with Fraa Jad's tacit agreement, decide to seek out Orolo. After a dangerous journey over the planet's frozen pole, they reunite with Orolo at an archaeological excavation of Orithena, an ancient concent destroyed by volcanic eruption. Orolo holds philosophical discussions with Erasmas about the nature of the cosmos and consciousness, and how he believes that the aliens are not simply from another planet, but from another cosmos that is influenced by Arbre. During one of the discussions, a small spacecraft lands in Orithena on an ancient analemma symbol within the excavation. (It is later revealed that Orolo had transmitted the analemma symbol to the spaceship and anticipated the landing at Orithena.) A female alien's body is found on board, dead of a recent gunshot wound. She has brought with her four vials of blood – one for each of four alien races – and evidence about their technology. Shortly thereafter, the aliens propel a massive metal rod at the volcano, triggering an eruption that destroys Orithena. Orolo sacrifices his life to ensure the recovery of the dead alien's remains and her blood samples, an event that leads to his canonization as Saunt Orolo. Erasmas travels to Saunt Tredegarh where he attends the Convox dedicated to dealing with the military, political, and technical issues raised by the existence of the alien ship in Arbre's orbit. Research is conducted on the samples from Orithena, and the aliens are found to come from planets in four parallel and distinct cosmi: Urnud, Tro, Laterre and Fthos.
== Awards and honours == Uhlmann was elected a Fellow of the Royal Society (FRS) in 2015. His certificate of election reads: Frank Uhlmann's discovery with Nasmyth of 'separase', the protease that cleaves the cohesive links between sister chromatids to trigger anaphase is a key contribution to our understanding of the cell cycle. He has made major contributions to our understanding of the mechanisms of sister chromatid cohesion, and their relationship to cell cycle regulation. He generated the first chromosome-wide high resolution maps of proteins involved in chromosome packaging and segregation. He showed that yeast cohesins accumulate at sites of converging transcription distinct from the sites where their loading factors bind, apparently reflecting interaction with the transcription apparatus; and that cohesin loading factors are recruited to specific chromosomal sites through interaction with the nucleosome remodelling complex Rsc. He has identified genes required for cohesion establishment, and shown that one of these, EcoI, acetylates cohesin during DNA replication, thereby locking it onto DNA and his studies of the link between cohesion regulation and the cell cycle have shown that as well as cleaving cohesin, separase promotes mitotic exit by activating the Cdc14 phosphatase in a protease-independent manner. In 2006, Uhlmann was also elected a member of the European Molecular Biology Organization (EMBO) and awarded the EMBO Gold Medal.
In animals, the MK-4 form of vitamin K2 is produced by conversion of vitamin K1 in the testes, pancreas, and arterial walls. While major questions still surround the biochemical pathway for this transformation, the conversion is not dependent on gut bacteria, as it occurs in germ-free rats and in parenterally administered K1 in rats. There is evidence that the conversion proceeds by removal of the phytyl tail of K1 to produce menadione (also referred to as vitamin K3) as an intermediate, which is then prenylated to produce MK-4.
Sources: en.wikipedia.org
=== Alternative medicine === The Food and Drug Administration (FDA) does not recommend alternative therapies to treat sexual dysfunction. Many products are advertised as "herbal viagra" or "natural" sexual enhancement products, but no clinical trials or scientific studies support the effectiveness of these products for the treatment of ED, and synthetic chemical compounds similar to sildenafil have been found as adulterants in many of these products. The FDA has warned consumers that any sexual enhancement product that claims to work as well as prescription products is likely to contain such a contaminant. A 2021 review indicated that ginseng had "only trivial effects on erectile function or satisfaction with intercourse compared to placebo".
Importantly, this results in a mixture of comic effects and of a serious aspiration to reflect on the continuing relevance of gender roles in the 21st century. The text can thus also be read as a literary plea for overcoming narrowly conceived identity politics and identity-based divisions.
As an analytical technique, RIS is useful based on some of its working operations – they include extremely low detection limit so that mass of samples could be identified up to the order of 10−15, the extremely high sensitivity and elemental selectivity useful in micro- and trace analysis when coupled with mass spectrometers, and ability of the pulsed laser ion source to produce pure isobaric ion beams. A major advantage of using resonance ionization is that it is a highly selective ionization mode; it is able to target a single type of atom among a background of many types of atoms, even when said background atoms are much more abundant than the target atoms. In addition, resonance ionization incorporates the high selectivity that is desired in spectroscopy methods with ultrasensitivity, thus making resonance ionization useful when analyzing complex samples with several atomic components. Resonance ionization spectroscopy (RIS) thus has a wide range of research and industrial applications. These include characterizing the diffusion and chemical reaction of free atoms in a gas medium, solid state surface analysis using direct sampling, studying the degree of concentration variations in a dilute vapor, detecting the allowable limits of number of particles needed in a semiconductor device, and estimating the flux of solar neutrinos on Earth.
The alternative to selling wholesale to distributors or retailers is to sell to retail customers either through company-owned stores or online. Advantages include receiving a larger slice of the price paid by the consumer; disadvantages include difficulty in reaching consumers. Direct selling is usually discussed as a model where products are sold through person-to-person selling outside a fixed retail establishment. The U.S. FTC uses this "outside a retail establishment" framing in its business guidance materials regarding multi level marketing.
Sources: en.wikipedia.org
=== Accusations of falsification and manipulation === According to Minakowski, pro-Polish activists decided to boycott the preparations for electoral commissions before the plebiscite to protest the unequal treatment of the Polish and German side and pro-German terror, which allowed German officials to falsify lists with eligible voters by adding names of dead or ineligible people. During the plebiscite, Germans transported pro-German voters to numerous locations, which allowed them to cast multiple votes. In Allenstein (Olsztyn), cards with pro-Polish votes were simply taken away by a German official, who declared that they were "invalid" and presented voters with pro-German cards. Voters were observed by the German police in polling stations. Pro-Polish voting cards were often hidden or taken away, and Polish controllers were removed from polling stations. A large number of Poles feared reprisals and did not turn out for the plebiscite.
ribozyme An RNA molecule with enzymatic activity, i.e. one that is capable of catalyzing one or more specific biochemical reactions, similar to protein enzymes. Ribozymes function in numerous capacities, including in ribosomes as part of the large subunit ribosomal RNA.
== Incidence == Numerous Laron syndrome patients are found in Israel among the country's diverse Jewish population composed of Jews from around the world, as well as patients outside Israel originally from communities of the Jewish diaspora, such as Egypt and Iraq. The original "Israeli cohort" of patients referred to Zvi Laron and colleagues beginning in 1958 consisted of 64 patients as of 2009, including 4 deceased patients. The countries of origin of these patients include Israel, Palestine, Jordan, Lebanon, Iran, Malta, Italy, Argentina, Ecuador, and Peru. A disproportionate number of people with the condition are found in remote villages in the Loja province of Ecuador. These individuals are descended from colonial-era Jewish-origin New Christian conversos (Sephardi Jews who themselves, or whose forebears, had been compelled to convert to Catholicism back in Spain) who had covertly migrated to Ecuador during the Spanish Conquest despite the Spanish Crown's prohibition of their emigration to its colonies and territories as a result of the Inquisition. Other patients include people of other Semitic non-Jewish origins, including from Saudi Arabia, Japan, and China.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.